Jeffrey D. Marrazzo - 29 Feb 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Director
Signature
/s/ Karen Brown, attorney-in-fact
Issuer symbol
PRME
Transactions as of
29 Feb 2024
Net transactions value
$0
Form type
4
Filing time
04 Mar 2024, 21:20:21 UTC
Previous filing
12 May 2023
Next filing
14 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +250,000 $0.000000 250,000 29 Feb 2024 Common Stock 250,000 $8.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest in full on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service through such vesting date.